oncnursingnews1d
Letter Warns Clinicians of Severe Infections With Pralsetinib for NSCLC
An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...
oncnursingnews1d
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.
oncnursingnews6d
Sexual Health During Breast Cancer: ‘Just Being Heard Is Important’
A nurse practitioner discusses how breast cancer treatment can impact sexual health, and how nurses and APPs can guide ...
oncnursingnews5d
Use of New Cancer Drugs Needs a ‘Tincture of Time and Information’
With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.
oncnursingnews4d
Bobbie J. Rimel, MD
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews5d
Yelena Shames, MSA, ACNP-BC, CNRN
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews7d
October 2024 FDA Approvals for Oncology
October 2024 brought 4 new FDA drug approvals in the oncology space. With new drug regimens in both the solid tumor and blood cancer space, it is essential that oncology nurses and advanced practice ...
oncnursingnews6d
Rajni Kannan
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews7d
Methotrexate’s Approval Expanded to Include Pediatric ALL
The FDA expanded the approval of methotrexate to include patients with pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis. The FDA approval of methotrexate (Jylamvo ...
oncnursingnews2d
David Reardon, MD
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...